Haleon Cuts Full-Year Guidance as Cough and Cold Sales Fall
Haleon lowered its full-year outlook, citing weaker sales of cough and cold medications. It now expects organic revenue growth of 2.5%.
Story updates
07:37:30 AM UTC
SquawkNews
UPDATE 1-Sensodyne maker Haleon cuts revenue growth forecast on weak flu season, China disruption Ad
07:38:24 AM UTC
SquawkNews
ATUALIZA 1-A Haleon, fabricante da Sensodyne, reduz a previsão de crescimento da receita devido à fr
07:38:30 AM UTC
SquawkNews
更新版 1-“舒适达”生产商Haleon因流感季表现疲软及中国市场受扰，下调营收增长预期 全文中补充了关于业绩指引及第三季度业绩的详细信息 路透社10月29日 - 英国消费健康公司Haleon（HLN
08:01:55 AM UTC
SquawkNews
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.
By Aimee LookAdvil-maker Haleon cut its outlook for the year, as lower sales of its cough and cold medications weighed on results.The company, which spun out of pharmaceutical group GSK in 2022, said it now expects full-year organic revenue growth at 2.5%. Haleon at its half-year results in July sa…